Avita: Micro-Cap With Big Time Approvals On Near Horizon

Dec. 17, 2022 9:00 AM ETAVITA Medical, Inc. (RCEL)14 Comments
Out of Ignorance profile picture
Out of Ignorance


  • Avita has a modest existing business selling its skin regeneration products.
  • Its shares have dropped recently despite several successes with the FDA.
  • Avita's near term catalysts offer sterling prospects for recovery to former highs and beyond.
  • While Avita has a nice potential upside it also has significant risks.

Public binoculars and Mountain Silhouettes at Sunrise. Foresight and vision for new business concepts and creative ideas. Alps, Allgau, Bavaria, Germany.


Severe skin conditions are often terribly disfiguring. Avita (NASDAQ:RCEL) has developed a cell based system to treat such conditions. Unfortunately it is struggling to scale its business as I will explain.

In my most recent Avita article, 05/2021's "AVITA: Recell's Growing Upside", ("Upside"), I

This article was written by

Out of Ignorance profile picture
Writing under the pseudonym "out of ignorance", I very much regard investing as a learning process. Investing failures are tuition paid. Investing successes enter the trove of lessons learned. In my Seeking Alpha articles I share my experience from decades of investing and from ~5 years of focused research on a variety of stocks, in recent years with a primary emphasis on healthcare stocks. I greatly appreciate those who take the time to share their reactions to articles, particularly those who share relevant anecdotes and experiences.

Disclosure: I/we have a beneficial long position in the shares of RCEL either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: I may buy or sell shares in any company mentioned over the next 72 hours.

Recommended For You

Comments (14)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.